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ABSTRACT 
Complement activation-related pseudoallergy 
(CARPA) is a frequent side effect of intravenous 
therapies with nanoparticle-containing drugs and 
biologicals that are recognized by the immune 
system as foreign. It is an acute infusion reac- 
tion dominated by cutaneous and hemodyna- 
mic changes, most significantly a cardiopulmo- 
nary distress involving major pulmonary hyper- 
tension, systemic hypotension and arrhythmias. 
Because CARPA is unpredictable by conven- 
tional allergy tests and it may be life threatening, 
it can represent a major barrier to the safe the- 
rapeutic application of many modern medicines, 
including liposomal drugs and monoclonal an- 
tibodies. This review summarizes and updates 
the facts and opens questions regarding this 
phenomenon, with particular focus on its por- 
cine model. 
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1. INTRODUCTION 
A causal relationship between immune changes and 
cardiovascular diseases is a well known phenomenon, for 
example, immune involvement in chronic heart failure 
via myocyte damage [1]. Another cause-effect relation- 
ship between the two systems is exemplified by drug and 
food allergies, or insect bites, which lead to the rapid 
development of a wide range of severe cardiopulmonary 
changes that can cause cardiac (anaphylactic) shock and 
death. Symptoms, e.g. arrhythmia, pulmonary edema, hy- 
potension, airway occlusion, respiratory distress and car- 
diac arrest are also typical of hypersensitivity reactions 
(HSRs) to certain drugs, where the underlying cause is 
the activation of the complement (C) system. These 
reactions were called C activation-related pseudoal- 
lergy (CARPA) [2]. 
2. DIFFERENT FORMS OF HSRS:  
CLASSICAL ANAPHYLAXIS AND  
CARPA 
HSRs have been categorized by Coombs and Gell in 
four groups from I to IV [3]. Type I reactions are defined 
as IgE-mediated acute reactions, while the rest of catego- 
ries included subacute or chronic immune changes trig- 
gered or mediated by IgG, immune complexes or lym- 
phocytes. However, it has increasingly been recognized 
that a substantial portion of acute allergic reactions, 
whose symptoms fit in Coombs and Gell’s Type I cate- 
gory, are actually not initiated or mediated by pre-exist- 
ing IgE antibodies. To distinguish between classical ana- 
phylactic reactions and these non-IgE-mediated ones, the 
latter category was termed pseudoallergy [4]. Pseudoal- 
lergy could be elicited by various agents e.g. radio-con- 
trast media (RCM), nonsteroidal anti-inflammatory drugs, 
analgesics, morphine and insect venoms, liposomes and 
micellar solvents, such as Cremophor EL (CrEL) in Ta- 
xol [2]. There are numerous data suggesting that C acti- 
vation is a common trigger mechanism of these reactions, 
where C3a and C5a activation products are generally in- 
volved [4]. The term, CARPA, was suggested on the ba- 
sis of this evidence [5]. 
Some symptoms of CARPA are the same as seen in 
common allergy or classical Type I reactions, while oth- 
ers are unique to C activation (Table 1). The most im- 
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portant distinguishing feature of CARPA seems to be the 
lack of pre-sensitization and reinforcement, that is al- 
ready the first exposure to a given noxious event or drug 
elicits maximal and in some cases fatal cardiovascular 
reaction. Upon repeated exposure the response decreases, 
frequently tachyphylaxis develops [6,7]. 
According to novel evidence summarized above a new 
scheme of hypersensitivity reactions was proposed by 
Szebeni et al. [2,5] with revision of the Type I category 
of Coombs and Gell’s classification (Figure 1). 
3. RELEVANCE OF CARPA IN HUMANS 
The clinical picture of CARPA includes cardiovascular 
(tachycardia or bradycardia, arrhythmia, hypo- and hy- 
pertension, chest pain, back pain), respiratory (tachypnea, 
bronchospasm, dyspnea), and cutaneous (flushing, urti- 
caria, erythema, pruritus) symptoms. 
 
Table 1. Symptoms of IgE-mediated Type I allergy and C acti- 
vation-related pseudoallergy (CARPA). 
Common symptoms 
Angioedema, asthma attack, bronchospasm, chest pain, chill,  
choking, confusion, conjunctivitis, coughing, cyanosis, death,  
dermatitis, diaphoresis, dispnoea, edema, erythema, feeling of  
imminent death, fever, flush, headache, hypertension, hypotension, 
hypoxemia, low back pain, lumbar pain, metabolic acidosis, nausea, 
pruritus, rash, rhinitis, shock, skin eruptions, sneezing, tachypnea, 
tingling sensations, urticaria, wheezing 
Unique symptoms 
IgE-mediated Type I  
Reaction arises after repeated exposure to the allergen  
Reaction is stronger upon repeated exposures  
Reaction does not cease without treatment  
Reaction rate is low (<2%) 
CARPA 
Reaction arises at first treatment (no prior exposure to allergen) 
Reaction is milder or absent upon repeated exposures 
Spontaneous resolution 
High reaction rate (up to 45%), average 7%, severe 2% 
Modified after Szebeni et al. [2]. 
 
 
Figure 1. Proposed new scheme of hypersensitivity reactions 
(Szebeni et al. [2]). 
The frequency of CARPA in the 5% - 45% range is 
much higher than classical anaphylactic reactions to 
drugs (for example, penicillin allergy occurs in <2%) [2]. 
Severe reactions can cause major anxieties, disruptions 
and exclusion of the patient from receiving a potentially 
useful life-saving treatment. These reactions can also be 
fatal in a small percentage of hypersensitive individuals, 
mainly those with a history of severe allergy and/or heart 
disease [8]. Complement activation during cardiopulmo- 
nary bypass with the involvement of C3a and C5a ana- 
phylatoxins was reported decades ago [9], which was 
later confirmed and the involvement of C-reactive pro- 
tein in association with postoperative arrhythmia was 
also described [10]. 
In the late 1990s PEG binding to the red blood cell 
(RBC) membrane was performed to cover red cell anti- 
gens, suggesting that such RBCs might be used as uni- 
versal/stealth RBCs, suitable for transfusion. However, in 
vivo studies in rabbits and in vitro testing of human sera 
were discouraging because of antigenicity and/or immu- 
nogenicity of PEG-RBCs, negating the benefits of mask- 
ing RBC blood group antigens with PEG. Later on simi- 
lar problems have been found with PEGylated lipo- 
somes [11], including a study by Brouwers et al. (2000) 
[12], which reported 3 severe infusion reactions out of 9 
patients obtaining Tc-99 m-PEG-liposomes for imaging 
of Crohn’s disease. The study dedicated to correlate C 
activation with HSRs gave account of 45% reaction rate 
in cancer patients infused with the liposome encapsulat- 
ing doxorubicine (Doxil) for the first time [13]. 
4. HEMODYNAMIC EFFECTS OF  
COMPLEMENT ACTIVATION IN  
ANIMAL MODELS 
It has long been known that the lipopolysaccharide- 
induced immediate and reversible thrombocytopenia and 
hypotension were prevented by prior depletion of the C3 
with the anticomplementary protein from cobra venom in 
conscious rabbits [14-16]. Later on it was also demon- 
strated that the anaphylatoxin C5a caused a reversible 
systemic arterial hypotension and decreased cardiac out- 
put while increased central venous pressure in control 
and neutropenic anesthetized rabbits. These hemody- 
namic effects were accompanied by increases in plasma 
prostanoid levels and neutropenia. Indomethacin abol- 
ished the C5a-induced hypotension. On the other hand, 
the thromboxane synthase inhibitor dazoxiben did not 
alter the hypotensive response but decreased changes in 
central venous pressure and decreased total peripheral 
circulatory resistance after C5a administration. Cimetidine, 
a H2-receptor antagonist attenuated the C5a-induced hy- 
potension and diminished prostanoid release [17]. 
A different way of activation of the alternative C path- 
way by intravenous injection of zymosan caused a range 
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of hemodynamic responses in anesthetized rats. Zymosan, 
at an intravenous dose of 2 mg/kg, increased extravasa- 
tion of 125I-labelled albumin in the lung. The zymo- 
san-induced response was not restricted to the lung since 
the hematocrit was also increased. The peak effect of 
zymosan was observed 15 min after treatment at the 
highest dose of 16 mg/kg i.v., and extravasation of 
plasma was still significant 60 min after treatment. The 
vascular permeability change in the lung was abolished 
by pre-treatment with the cyclooxygenase inhibitors, in- 
domethacin or ketoprofen and the lipoxygenase and cy- 
clooxygenase inhibitor, BW 755C, and no plasma extra- 
vasation was found in rats made leucopenic by rabbit 
anti-neutrophil serum. On the other hand, the PAF an- 
tagonist, WEB 2086, the antihistamine, mepyramine or 
the non-selective serotonin antagonist, methysergide did 
not affect the response to zymosan [18]. 
The dose-dependent hemodynamic and respiratory ef- 
fects of zymosan began with a transient increase in right 
ventricular systolic pressure and respiratory rate, and 
then a drop in blood pressure was noted lasting for 15 - 
30 min at the doses of 3 and 8 mg/kg. The right ven- 
tricular systolic pressure decreased in parallel with the 
blood pressure at the higher dose of zymosan. WEB 2086 
largely prevented the decreases in blood pressure and 
right ventricular systolic pressure, while indomethacin 
attenuated the tachypnea and the increase in right ven- 
tricular systolic pressure but augmented the drop in 
blood pressure and right ventricular systolic pressure. 
Complement activation was verified by reduced C he- 
molytic activity. These results demonstrated that in the 
rat, C activation by zymosan lead to prostanoid-mediated 
pulmonary and PAF-mediated systemic vascular effects 
[18]. 
5. HEMODYNAMIC EFFECTS OF  
LIPOSOMES AS A CONSEQUENCE  
OF COMPLEMENT ACTIVATION 
One of the first observations with nanoparticles was 
made with liposome-encapsulated hemoglobin (LEH) 
using hydrogenated soy lecithin. Injection of LEH in the 
conscious rat elevated mean arterial pressure and heart 
rate but decreased platelet count with a proportional in- 
crease in plasma TXB2 concentration. Liposome vehicles 
decreased blood pressure and platelet count but increased 
heart rate and plasma TXB2 levels. All effects were tran- 
sient [19]. Using synthetic distearoyl phosphatidylcho- 
line-based liposomes for encapsulating hemoglobin mar- 
kedly diminished the hemodynamic effects. Injection of 
the improved preparation caused only a small tachycar- 
dia and elevation in plasma TXB2 level [20]. Pretreat- 
ment with the PAF antagonist BN 50739 abolished all 
changes caused by the distearoyl phosphatidylcholine- 
based liposome-encapsulated hemoglobin [21]. 
A big advance in understanding the drug-induced hy- 
persensitive reactions was made by the discovery that in- 
travenous injection of hemoglobin-containing liposomes 
and to a lesser extent empty liposomes but not hemoglo- 
bin decreased the plasma C hemolytic activity and in- 
creased the plasma TXB2 level. EGTA/Mg2+ did not in- 
hibit C consumption induced by hemoglobin-containing 
liposomes in rat plasma but pre-heating rat plasma to 
50˚C abolished C consumption. Treatment with the solu- 
ble C receptor type 1 (sCR1) or C depletion with the co- 
bra venom factor decreased the liposome-induced rise in 
plasma TXB2 level. These results suggested that hemo- 
globin containing liposomes activated the alternative C 
pathway [22,23]. 
Since liposomes do not contain proteins, they likely 
activate the innate immunity. In fact, the size and shape 
of liposomes are similar to those of pathogenic viruses, 
nanobacteria and subcellular organelles. Therefore, lipo- 
somes are recognized by the nonspecific immune system 
as pathogens, so liposomes and other nanoparticles can 
activate efficient eliminatory mechanisms [24]. 
The pioneering findings related to CARPA were fol- 
lowed by the demonstration that liposomal drugs or li- 
posomes, in general, caused immediate cardiovascular 
hypersensitivity reactions in anesthetized pigs. Intrave- 
nous injection of large multilamellar liposomes raised 
pulmonary arterial pressure, heart rate, pulmonary vas- 
cular resistance, systemic vascular resistance while caus- 
ed a decrease in cardiac output [4,25]. These effects were 
dose-dependent and repeatable for several times in the 
same animal, exhibiting no tachyphylaxis. The rises in 
pulmonary arterial pressure correlated with elevations in 
plasma TXB2 levels. The cardiovascular hypersensitivity 
reactions were inhibited by an anti-C5a monoclonal an- 
tibody, sCR1, or indomethacin. The liposome-induced 
increase in C5a production was mediated via the classi- 
cal C activation pathway and liposomes bound IgG and 
IgM natural antibodies in pig serum in vitro. Zymosan 
and hemoglobin-containing liposomes and empty lipo- 
somes caused nearly equal pulmonary artery pressure 
changes [4,25]. 
Further studies identified that multilamellar liposomes, 
doxorubicin-containing liposomes (Doxil) or ampho- 
tericine B-containing liposomes (Ambisome) evoked car- 
diac anaphylaxis in pigs. Intravenous injection of lipo- 
somes rapidly resulted in dose-dependent hemody- 
namic (systemic hypotension, pulmonary hypertension, 
decreased cardiac output), respiratory (decreased end- 
tidal pCO2) and mild to severe cardiac changes such as 
tachycardia and/or paradoxical bradycardia, arrhythmias, 
ST depression, T-wave elevation, atrioventricular block, 
ventricular fibrillation, and cardiac arrest (Figure 2). The 
severity of the cardiac effects significantly correlated 
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with the liposome-mediated production of C5a in pig 
serum in vitro. Zymosan and recombinant human (rhu) 
C5a almost fully reproduced the above effects while 
pre-treatment with sCR1, an inhibitor of C activation via 
the classical and alternative pathways, or with the anti- 
porcine C5a antibody GS1 markedly reduced the pul- 
monary and cardiac abnormalities [26]. 
Similar responses were obtained in anaesthetized rats. 
Intravenous injection of high cholesterol (71 mole %) 
containing multilamellar liposomes at low dose (8 mg/kg) 
induced a rapidly developing drop in blood pressure, 
bradycardia, arrhythmia and tachypnea with clear signs 
of pulmonary edema. These responses faded in 10 - 30 
min and repeated injections elicited a similar response. 
Blockade of the C system with cobra venom prevented 
the hypotensive response even after the injection of a 
lethal dose of liposomes (30 mg/kg). Pre-treatment with 
SQ 30,741, a TXA2 receptor inhibitor was also protective 
against the liposome-induced cardiopulmonary distress 
[28]. 
6. SPECIES DEPENDENCE OF THE  
LIPOSOME-INDUCED CARPA  
Comparison of the liposome-induced or nanoparti- 
cle-dependent CARPA across species revealed strong 
interspecies variability [8]. Liposomes with high choles- 
terol-content (71 mole %) consumed 18% of total hemo- 
lytic C activity in rat sera, while the same liposome pre- 
paration consumed 100% of the activity in pig sera and 
more than 70% of the activity in human sera, in vitro. 
Cholesterol-poor liposomes consumed approximately 
only 2% of total hemolytic C activity in rat sera, but as 
much as 20% of pig and human hemolytic activity [28]. 
 
 
Figure 2. Cardiopulmonary changes following intravenous 
administration of Ambisome at 0.01 mg/kg, 80 nM phosphol- 
ipid/kg. PAP, pulmonary arterial pressure; SAP, systemic arte- 
rial pressure; arrows indicate the time of injection (Szebeni, et 
al. [27]). 
The most sensitive cardiopulmonary distress model for 
the detection of CARPA in vivo is the anesthetized pig 
established in our laboratory (see experimental arrange- 
ment in Figure 3). Testing liposomes and nanoparticles 
in pigs can best predict human C activation and reactiv- 
ity. 
7. DEPENDENCE OF CARPA-INDUCING  
ACTIVITY ON THE  
CHARACTERISTICS OF LIPOSOMES 
The liposome-induced C activation is highly depend- 
ent on the liposome characteristics. The reactivity of 
various liposome preparations can be evaluated by meas- 
uring the formation of S protein-bound C-terminal com- 
plex (SC5b-9) in normal human serum, in vitro [27]. It 
has been clearly shown that drug-loaded liposomes 
caused much stronger reactions than empty ones. The 
free drug binds to the liposome surface, which alters 
the surface characteristics of the liposome leading to 
enhanced C activation. Further, binding of free drug to 
the liposome surface causes aggregation and larger 
liposomes activate the C system stronger than small 
ones [27]. 
Already the early studies disclosed that multilamellar 
vesicles with high cholesterol content (71 mole %) 
caused a drastic drop in blood pressure while administra- 
tion of the same dose of low cholesterol-containing (43 
mole %) multilamellar vesicles did not change blood 
pressure [28]. An explanation for the role of cholesterol 
can be that cholesterol-loaded liposomes bind more to 
naturally occurring anticholesterol antibodies. In fact, 
liposomes containing 71% cholesterol bound 9-fold high- 
er amount of murine monoclonal anticholesterol anti- 
bodyies than liposomes containing 43% cholesterol. 
Similar results were observed when normal and cho- 
lesterol enriched liposomes were incubated with hu- 
man sera [28]. 
It is generally observed that negative charge on the 
 
 
Figure 3. Assessing CARPA and cardiopulmonary distress by 
nanoparticles in the pig (Szebeni et al. [24]). 
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liposome surface increased reactivity. The strongly nega- 
tive liposomes containing fully hydrogenated soy phos- 
phatidylcholine-cholesterol-soy phosphatidyl-glycerol induc- 
ed much stronger C activation in human sera than the 
comparable less negative vesicles [27]. 
Surface characteristics of liposomes can also alter their 
C activating properties. A “structure-activity” relation- 
ship of nanoparticles with various surface configurations 
have shown that alteration from “mushroom” to “brush” 
surface configuration shifted C activation from C1q-de- 
pendent classical to lectin pathway and also reduced C 
activation [29]. 
Liposomes containing poly(ethylene imine) induced 
significant and concentration-dependent C activation 
whereas its two PEGylated poly(ethylene imine) deriva- 
tives were without an effect in human sera. The same 
difference between the poly(ethylene imine) liposomes 
and their PEGylated derivatives were demonstrated in 
the pig model after intravenous administration, showing 
CARPA, i.e. transient cardiopulmonary distress. It was 
also found that poly(ethylene imine) liposomes caused 
both self- and cross-tolerance [30]. 
8. SUMMARY AND CONCLUSIONS 
Complement Activation-Related Pseudoallergy (CARPA) 
is a detrimental reaction of the cardiopulmonary system 
propelled by the hypersensitive reaction of the immune 
system in response to various C activating allergens. It 
can be clearly differentiated from classical anaphylatoxic 
reactions, while in contrast to the IgE mediation of clas- 
sical allergy, activation of the C system plays a crucial 
role in the mechanism of action. Pseudoallergic reac- 
tions bear important human relevance, due to their high 
incidence upon food or drug-related exposures, insect 
bites, or even surgical interventions without prior sensi- 
tization. New drug formulations, especially nanomedici- 
nal (e.g. liposomal) products resulted in new challenges 
because of their CARPA-inducing characteristics. 
Cardiovascular and pulmonary symptoms of CARPA 
are ranging from mild to severe reactions. The latter could 
result in respiratory and/or cardiac arrest, as well as huge 
and sudden changes in pulmonary and systemic arterial 
pressures. The sensitivity to CARPA widely varies among 
species, the most sensitive are being humans and pigs, 
while dogs are less sensitive and rodents seem to be rela- 
tively insensitive. While this special hypersensitive reac- 
tion has important clinical relevance nowadays, animal 
models of CARPA that are potentially capable of evalu- 
ating the pseudoallergic properties of novel drug candi- 
dates are of utmost importance. The porcine model of 
CARPA proved to be the best model so far to predict 
cardiovascular and pulmonary changes evoked by vari- 
ous drug injections. The only disadvantage of the pig test 
is that it is rather labor consuming and also expensive; 
therefore it is inappropriate for large scale screening 
purposes. Therefore, it still leaves room for the develop- 
ment of other (e.g. rodent) models in order to predict the 
cardiopulmonary side effects of new chemical entities 
due to CARPA. 
 
REFERENCES 
[1] Fildes, J.E., Shaw, S.M., Yonan, N. and Williams, S.G. 
(2009) The immune system and chronic heart failure: Is 
the heart in control? Journal of the American College of 
Cardiology, 53, 1013-1020. 
doi:10.1016/j.jacc.2008.11.046 
[2] Szebeni, J. (2005) Complement activation-related pseu- 
doallergy: A new class of drug-induced acute immune 
toxicity. Toxicology, 216, 106-121. 
doi:10.1016/j.tox.2005.07.023 
[3] Coombs, R.R.A. and Gell, P.G.H. (1968) Classification of 
allergic reactions responsible for drug hypersensitivity 
reactions. In: Coombs, R.R.A. and Gell, P.G.H., Eds., Cli- 
nical Aspects of Immunology, Davis, Philadelphia, 575- 
596. 
[4] Szebeni, J., Fontana, J.L., Wassef, N.M., Mongan, P.D., 
Morse, D.S., Dobbins, D.E., Stahl, G.L., Bunger, R. and 
Alving, C.R. (1999) Hemodynamic changes induced by 
liposomes and liposome-encapsulated hemoglobin in pigs: 
A model for pseudoallergic cardiopulmonary reactions to 
liposomes. Role of complement and inhibition by soluble 
CR1 and anti-C5a antibody. Circulation, 99, 2302-2309. 
doi:10.1161/01.CIR.99.17.2302 
[5] Szebeni, J., Baranyi, L., Savay, S., Milosevits, J., Bunger, 
R., Laverman, P., Metselaar, J.M., Storm, G., Chanan- 
Khan, A., Liebes, L., Muggia, F.M., Cohen, R., Barenholz, 
Y. and Alving, C.R. (2002) Role of complement active- 
tion in hypersensitivity reactions to doxil and hynic PEG 
liposomes: Experimental and clinical studies. Journal of 
Liposome Research, 12, 165-172. 
doi:10.1081/LPR-120004790 
[6] Szebeni, J., Bedocs, P., Csukas, D., Rosivall, L., Bunger, 
R. and Urbanics, R. (2012) A porcine model of comple- 
ment-mediated infusion reactions to drug carrier nano- 
systems and other medicines. Advanced Drug Delivery 
Reviews, 64, 1706-1716. 
doi:10.1016/j.addr.2012.07.005 
[7] Szebeni, J., Bedocs, P., Urbanics, R., Bunger, R., Rosivall, 
L., Toth, M. and Barenholz, Y. (2012) Prevention of infu- 
sion reactions to PEGylated liposomal doxorubicin via 
tachyphylaxis induction by placebo vesicles: A porcine 
model. Journal of Controlled Release: Official Journal of 
the Controlled Release Society, 160, 382-387. 
[8] Szebeni, J., Alving, C.R., Rosivall, L., Bunger, R., Ba- 
ranyi, L., Bedocs, P., Toth. M. and Barenholz, Y. (2007) 
Animal models of complement-mediated hypersensitivity 
reactions to liposomes and other lipid-based nanoparticles. 
Journal of Liposome Research, 17, 107-117. 
doi:10.1080/08982100701375118 
[9] Chenoweth, D.E., Cooper, S.W., Hugli, T.E., Stewart, 
R.W., Blackstone, E.H. and Kirklin, J.W. (1981) Com-
Copyright © 2013 SciRes.                                                                    OPEN ACCESS 
L. Dézsi et al. / Health 5 (2013) 1032-1038 1037
plement activation during cardiopulmonary bypass: Evi- 
dence for generation of C3a and C5a anaphylatoxins. The 
New England Journal of Medicine, 304, 497-503. 
doi:10.1056/NEJM198102263040901 
[10] Bruins, P., te Velthuis, H., Yazdanbakhsh, A.P., Jansen, 
P.G., van Hardevelt, F.W., de Beaumont, E.M., Wildevuur, 
C.R., Eijsman, L., Trouwborst, A. and Hack, C.E. (1997) 
Activation of the complement system during and after 
cardiopulmonary bypass surgery: Postsurgery activation 
involves C-reactive protein and is associated with post- 
operative arrhythmia. Circulation, 96, 3542-3548. 
doi:10.1161/01.CIR.96.10.3542 
[11] Garay, R.P., El-Gewely, R., Armstrong, J.K., Garratty, G. 
and Richette, P. (2012) Antibodies against polyethylene 
glycol in healthy subjects and in patients treated with 
PEG-conjugated agents. Expert Opinion on Drug Deliv- 
ery, 9, 1319-1323. 
doi:10.1517/17425247.2012.720969 
[12] Brouwers, A.H., De Jong, D.J., Dams, E.T., Oyen, W.J., 
Boerman, O.C., Laverman, P., Naber, T.H., Storm, G. and 
Corstens, F.H. (2000) Tc-99m-PEG-Liposomes for the 
evaluation of colitis in Crohn’s disease. Journal of Drug 
Targeting, 8, 225-233. doi:10.3109/10611860008997901 
[13] Chanan-Khan, A., Szebeni, J., Savay, S., Liebes, L., Ra- 
fique, N.M., Alving, C.R. and Muggia, F.M. (2003) Com- 
plement activation following first exposure to pegylated 
liposomal doxorubicin (Doxil): Possible role in hypersen- 
sitivity reactions. Annals of Oncology, 14, 1430-1437. 
doi:10.1093/annonc/mdg374 
[14] Ulevitch, R.J., Cochrane, C.G., Henson, P.M., Morrison, 
D.C. and Doe, W.F. (1975) Mediation systems in bacterial 
lipopolysaccharide-induced hypotension and disseminat- 
ed intravascular coagulation. I. The role of complement. 
The Journal of Experimental Medicine, 142, 1570-1590. 
doi:10.1084/jem.142.6.1570 
[15] Ulevitch, R.J. and Cochrane, C.G. (1978) Role of com- 
plement in lethal bacterial lipopolysaccharide-induced hy- 
potensive and coagulative changes. Infection and Immu- 
nity, 19, 204-211. 
[16] Ulevitch, R.J. and Cochrane, C.G. (1977) Complement- 
dependent hemodynamic and hematologic changes in the 
rabbit. Inflammation, 2, 199-216. 
doi:10.1007/BF00917596 
[17] Lundberg, C., Marceau, F. and Hugli, T.E. (1987) C5a- 
induced hemodynamic and hematologic changes in the 
rabbit. Role of cyclooxygenase products and polymor- 
phonuclear leukocytes. The American Journal of Pathol- 
ogy, 128, 471-483. 
[18] Damas, J. and Lagneaux, D. (1991) Dissociation between 
the effects of zymosan on the systemic and pulmonary 
vessels of the rat. British Journal of Pharmacology, 104, 
559-564. doi:10.1111/j.1476-5381.1991.tb12468.x 
[19] Rabinovici, R., Rudolph, A.S. and Feuerstein, G. (1989) 
Characterization of hemodynamic, hematologic, and bio- 
chemical responses to administration of liposome-en- 
capsulated hemoglobin in the conscious, freely moving 
rat. Circulatory Shock, 29, 115-132. 
[20] Rabinovici, R., Rudolph, A.S. and Feuerstein, G. (1990) 
Improved biological properties of synthetic distearoyl 
phosphatidyl choline-based liposome in the conscious rat. 
Circulatory Shock, 30, 207-219. 
[21] Rabinovici, R., Rudolph, A.S., Yue, T.L. and Feuerstein, 
G. (1990) Biological responses to liposome-encapsulated 
hemoglobin (LEH) are improved by a PAF antagonist. 
Circulatory Shock, 31, 431-445. 
[22] Szebeni, J., Wassef, N.M., Spielberg, H., Rudolph, A.S. 
and Alving, C.R. (1994) Complement activation in rats by 
liposomes and liposome-encapsulated hemoglobin: Evi- 
dence for anti-lipid antibodies and alternative pathway 
activation. Biochemical and Biophysical Research Com- 
munications, 205, 255-263. 
doi:10.1006/bbrc.1994.2658 
[23] Szebeni, J., Spielberg, H., Cliff, R.O., Wassef, N.M., 
Rudolph, A.S. and Alving, C.R. (1997) Complement ac- 
tivation and thromboxane secretion by liposome-encap- 
sulated hemoglobin in rats in vivo: Inhibition by soluble 
complement receptor type 1. Artificial Cells, Blood Sub- 
stitutes, and Immobilization Biotechnology, 25, 347-355. 
doi:10.3109/10731199709118925 
[24] Szebeni, J., Muggia, F., Gabizon, A. and Barenholz, Y. 
(2011) Activation of complement by therapeutic lipo- 
somes and other lipid excipient-based therapeutic prod- 
ucts: Prediction and prevention. Advanced Drug Delivery 
Reviews, 63, 1020-1030. 
doi:10.1016/j.addr.2011.06.017 
[25] Wassef, N.M., Johnson, S.H., Graeber, G.M., Swartz, 
G.M., Jr., Schultz, C.L., Hailey, J.R., Johnson, A.J., Taylor, 
D.G., Ridgway, R.L. and Alving, C.R. (1989) Anaphylac- 
toid reactions mediated by autoantibodies to cholesterol 
in miniature pigs. Journal of Immunology, 143, 2990- 
2995. 
[26] Szebeni, J., Baranyi, L., Savay, S., Bodo, M., Milosevits, 
J., Alving, C.R. and Bunger, R. (2006) Complement acti- 
vation-related cardiac anaphylaxis in pigs: Role of C5a 
anaphylatoxin and adenosine in liposome-induced ab- 
normalities in ECG and heart function. American Journal 
of Physiology. Heart and Circulatory Physiology, 290, 
H1050-H1058. doi:10.1152/ajpheart.00622.2005 
[27] Szebeni, J., Bedocs, P., Rozsnyay, Z., Weiszhar, Z., Ur- 
banics, R., Rosivall, L., Cohen, R., Garbuzenko, O., Ba- 
thori, G., Toth, M., Bunger, R. and Barenholz, Y. (2012) 
Liposome-induced complement activation and related car- 
diopulmonary distress in pigs: Factors promoting reacto- 
genicity of Doxil and AmBisome. Nanomedicine: Nano- 
technology, Biology, and Medicine, 8, 176-184. 
doi:10.1016/j.nano.2011.06.003 
[28] Baranyi, L., Szebeni, J., Savay, S., Bodo, M., Basta, M., 
Bentley, T.B., Bunger, R. and Alving, C.R. (2003) Com- 
plement-dependent shock and tissue damage induced by 
intravenous injection of cholesterol-enriched liposomes in 
rats. The Journal of Applied Research in Clinical and 
Experimental Therapeutics, 3, 1-19. 
[29] Hamad, I., Al-Hanbali, O., Hunter, A.C., Rutt, K.J., An- 
dresen, T.L. and Moghimi, S.M. (2010) Distinct polymer 
architecture mediates switching of complement activation 
pathways at the nanosphere-serum interface: Implications 
for stealth nanoparticle engineering. ACS Nano, 4, 6629- 
6638. doi:10.1021/nn101990a 
Copyright © 2013 SciRes.                                                                    OPEN ACCESS 
L. Dézsi et al. / Health 5 (2013) 1032-1038 
Copyright © 2013 SciRes.                                                                    OPEN ACCESS 
1038 
[30] Merkel, O.M., Urbanics, R., Bedocs, P., Rozsnyay, Z., 
Rosivall, L., Toth, M., Kissel, T. and Szebeni, J. (2011) In 
vitro and in vivo complement activation and related ana- 
phylactic effects associated with polyethylenimine and 
polyethylenimine-graft-poly(ethylene glycol) block co-
polymers. Biomaterials, 32, 4936-4942. 
doi:10.1016/j.biomaterials.2011.03.035 
 
